286 related articles for article (PubMed ID: 37256234)
1. Pharmacogenomic-guided dosing of fluoropyrimidines beyond
Maslarinou A; Manolopoulos VG; Ragia G
Front Pharmacol; 2023; 14():1184523. PubMed ID: 37256234
[TBL] [Abstract][Full Text] [Related]
2. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
[TBL] [Abstract][Full Text] [Related]
3. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients:
Ragia G; Maslarinou A; Atzemian N; Biziota E; Koukaki T; Ioannou C; Balgkouranidou I; Kolios G; Kakolyris S; Xenidis N; Amarantidis K; Manolopoulos VG
Front Pharmacol; 2023; 14():1248898. PubMed ID: 37781702
[No Abstract] [Full Text] [Related]
4. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
[TBL] [Abstract][Full Text] [Related]
5.
Lešnjaković L; Ganoci L; Bilić I; Šimičević L; Mucalo I; Pleština S; Božina N
Pharmacogenomics; 2023 Jan; 24(2):93-106. PubMed ID: 36636997
[TBL] [Abstract][Full Text] [Related]
6. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
[TBL] [Abstract][Full Text] [Related]
8. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
[TBL] [Abstract][Full Text] [Related]
9. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
Conti V; De Bellis E; Manzo V; Sabbatino F; Iannello F; Dal Piaz F; Izzo V; Charlier B; Stefanelli B; Torsiello M; Iannaccone T; Coglianese A; Colucci F; Pepe S; Filippelli A
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899374
[TBL] [Abstract][Full Text] [Related]
10. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
11. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
[TBL] [Abstract][Full Text] [Related]
12. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
13. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
14. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
[TBL] [Abstract][Full Text] [Related]
15. Near Miss or Standard of Care?
Winquist LE; Sanatani M; Kim RB; Winquist E
Curr Oncol; 2020 Dec; 28(1):94-97. PubMed ID: 33704179
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
17. A Novel
Tong CC; Lam CW; Lam KO; Lee VHF; Luk MY
Front Oncol; 2018; 8():279. PubMed ID: 30087856
[No Abstract] [Full Text] [Related]
18. Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report.
Baiardi G; Clavarezza M; Stella M; Casazza S; De Censi A; Mattioli F
Cancer Chemother Pharmacol; 2023 May; 91(5):435-439. PubMed ID: 36890284
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
